TRIANGLE PHARMACEUTICALS INC

Form 4 April 10, 2001

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549								
/ / CHECK THIS BOX IF NO LONGER SUBJECT TO SECTION 16. FORM 4 OR FORM 5 OBLIGATIONS MAY CONTINUE. SEE INSTRUCTION 1(b). (Print or Type Responses)		STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of Section 17(a) of the Public Utility Holding Company Act of 1935 Section 30(f) of the Investment Company Act of 1940								
1. Name and Add	lress of Report	ting Person*	2. Issuer Name AND Ticker or Trading Symbol 6. 1							
Fleming	Standish	М.	Triangle Pharmaceuticals, Inc. (VIRS)							
(Last)	(First)		3. IRS or Social Security 4. Statement for Number of Reporting Month/Year Person (Voluntary)							
c/o Forward Ven 9255 Towne Cent	tre Drive, Suit		March 2001							
	(Street)		7. 5. If Amendment,							
San Diego	CA	92121	\ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\							
(City)	(State)	(Zip)	TABLE I - NON-DERIVATIVE SECURITIES ACQUIRED, D							
1. Title of Security (Instr. 3)		2. Trans- action Date (Month/	3. Trans- action Code (Instr. 8) 4. Securities Acquired (A) Amount of Sec							
		Day/ Year)	(A) or Code V Amount (D) Price (Instr. and 4)							
Common Stock										
Common Stock			817							
Common Stock			1,545							
Common Stock			4,122							
Common Stock			520 , 000							
Common Stock			233,663							

Series B Convertible Preferre	d Stock	3/8/2001	Р	120,704	Α	\$60	120,704	
Series B Convertible Preferre	d Stock	3/8/2001	P	12,629	A	\$60	12,629	
* If the form is filed by mor Reminder: Report on a separat	e than o	ne reportin	g person, Sl	EE Instruction	4 (b)) (v).		
FORM 4 (CONTINUED) T.				S ACQUIRED, DI ANTS, OPTIONS,		•		
1. Title of Derivative Securi (Instr. 3)	 ty 2	sion or Exercise Price of	action	4. Transac- tion Code)	5. Number of Deriv- ative Securities Ac quired (A) or Dis- posed of (D) (Instr. 3, 4, and 5		
				Code V			(D)	

7.	Title and Amount lying Securities (Instr. 3 and 4)	of Under-	8.	Price of Deriv-ative Security (Instr. 5)	Number of Deriv- ative Securi- ties Bene- ficially Owned at End of	10.	Owner- ship Form of De- rivative Secu- rity: Direct (D) or Indi-	11.	Nature of Indirect Beneficial Ownership (Instr.	4)
	Title	Number of Shares			Month (Instr. 4)		rect (I) (Instr. 4)			

Explanation of Responses:

- (+) Mr. Fleming disclaims beneficial ownership of these shares other than to the extent of his in pecuniary interests.
- (1) Represents a distribution of 3,082 shares made by Forward II Associates, L.P., of which Mr. F received 656 shares in his individual capacity.
 In prior reports, Mr. Fleming has reported beneficial ownership of the distributed shares.
- (2) Represents shares held by the Fleming Family Trust, of which Mr. Fleming is a co-trustee.
- (3) Represents shares held by the Fleming Family Children's Trust, of which Mr. Fleming is a co-t (4) Represents all shares held by Forward II Associates, L.P. (to the extent of its own partnersh II, L.P.).
- (5) Represents all shares held by Forward Ventures II, L.P.
- (6) Represents all shares held by Forward Ventures III, L.P., of which Forward III Associates, L. which Mr. Fleming is a managing member.
- (7) Represents all shares held by Forward Ventures IV, L.P., of which Forward IV Associates, L.L. which Mr. Fleming is a managing member.
- (8) Represents all shares held by Forward Ventures IV B, L.P., of which Forward IV Associates, L. which Mr. Fleming is a managing member.

**Intentional misstatements or omissions of facts constitute
Federal Criminal Violations. SEE 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

/s/ Standish
----**Signature of

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, SEE Instruction 6 for procedure.

3